Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13579113 | 0.87 | PGR (0.77) | PGRNR3C1 | |
| SCHEMBL5519179 | 0.86 | PGR (0.76) | PGRNR3C1 | |
| SCHEMBL61743 | 0.86 | PGR (1.00) | PGRNR3C1 | |
| SCHEMBL5512567 | 0.85 | PGR (0.74) | PGRNR3C1 | |
| SCHEMBL3869144 | 0.85 | PGR (0.77) | PGRNR3C1 | |
| SCHEMBL4185522 | 0.85 | PGR (0.98) | PGRNR3C1 | |
| SCHEMBL3874234 | 0.84 | PGR (0.72) | PGRNR3C1 | |
| SCHEMBL5512561 | 0.84 | PGR (0.72) | PGRNR3C1 | |
| SCHEMBL5512888 | 0.84 | PGR (0.72) | PGRNR3C1 | |
| SCHEMBL5516097 | 0.84 | PGR (0.72) | PGRNR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 221 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4643858-A1 | METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF UTERINE DISEASE | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-11-05 | — | — | EP | claimed |
| WO-2024175760-A1 | METHODS FOR THE TREATMENT OF ENDOMETRIOSIS | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-08-29 | — | — | WO | claimed |
| EP-3277285-B1 | ESTRIOL FOR REDUCING CORTICAL GRAY MATTER ATROPHY | UNIV CALIFORNIA (US) | 2024-07-17 | — | — | EP | claimed |
| US-20230346820-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | THE SCRIPPS RESEARCH INSTITUTE | 2023-11-02 | — | — | US | claimed |
| EP-3200802-B1 | COMPOSITIONS AND METHODS FOR MAINTAINING COGNITIVE FUNCTION | UNIV CALIFORNIA (US) | 2023-07-12 | — | — | EP | claimed |
| US-20230126310-A1 | COMPOSITIONS FOR CORONAVIRUS INFECTION TREATMENT AND/OR PREVENTION | FRAUNHOFER GES FORSCHUNG (DE) | 2023-04-27 | — | — | US | claimed |
| EP-4126234-A1 | COMPOSITIONS FOR CORONAVIRUS INFECTION TREATMENT AND/OR PREVENTION | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2023-02-08 | — | — | EP | claimed |
| US-20230000832-A1 | USE OF NEUROPILIN ANTAGONISTS FOR THE TREATMENT OF ENDOMETRIOSIS | ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP) (FR) | 2023-01-05 | — | — | US | claimed |
| EP-4065224-A1 | USE OF NEUROPILIN ANTAGONISTS FOR THE TREATMENT OF ENDOMETRIOSIS | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2022-10-05 | — | — | EP | claimed |
| EP-3943079-A1 | THERAPEUTIC AND METHOD OF USE | Predictive Therapeutics, LLC (US) | 2022-01-26 | — | — | EP | claimed |
| WO-2006116498-A2 | PURIFIED FORM OF TANAPROGET | WYETH (US) | 2006-11-02 | — | — | WO | claimed |
| US-20060009428-A1 | Cyclic progestin regimens and kits | WYETH (US) | 2006-01-12 | — | — | US | claimed |
| EP-1531824-A4 | CYCLOTHIOCARBAMATIVE DERIVATIVES AS PR MODULATORS AND USE THEREOF FOR TREATMENT OF SKIN DISORDERS | WYETH CORP (US) | 2005-09-21 | — | — | EP | claimed |
| EP-1515725-A4 | USE OF CYCLOTHIOCARBAMATE DERIVATIVES IN TREATMENT OF HORMONE-RELATED CONDITIONS | WYETH CORP (US) | 2005-09-21 | — | — | EP | claimed |
| EP-1531824-A2 | CYCLOTHIOCARBAMATIVE DERIVATIVES AS PR MODULATORS AND USE THEREOF FOR TREATMENT OF SKIN DISORDERS | Wyeth (US) | 2005-05-25 | — | — | EP | claimed |
| EP-1515725-A2 | USE OF CYCLOTHIOCARBAMATE DERIVATIVES IN TREATMENT OF HORMONE-RELATED CONDITIONS | Wyeth (US) | 2005-03-23 | — | — | EP | claimed |
| US-20040014798-A1 | Cyclothiocarbamate derivatives as progesterone receptor modulators and methods of treating skin disorders | WYETH | 2004-01-22 | — | — | US | claimed |
| US-20040006060-A1 | Methods of treating hormone-related conditions using cyclothiocarbamate derivatives | WYETH | 2004-01-08 | — | — | US | claimed |
| WO-2004000801-A2 | USE OF CYCLOTHIOCARBAMATE DERIVATIVES IN TREATMENT OF HORMONE-RELATED CONDITIONS | WYETH (US) | 2003-12-31 | — | — | WO | claimed |
| WO-2004000230-A2 | CYCLOTHIOCARBAMATIVE DERIVATIVES AS PR MODULATORS AND USE THEREOF FOR TREATMENT OF SKIN DISORDERS | WYETH (US) | 2003-12-31 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006060-A1 | Methods of treating hormone-related conditions using cyclothiocarbamate derivatives | ESRRA, GNRHR, ESRRG | PGR 46/4885NR3C1 79/4885 |
| US-20230000832-A1 | USE OF NEUROPILIN ANTAGONISTS FOR THE TREATMENT OF ENDOMETRIOSIS | NRP1, PGR, TNFRSF1A | PGR 2/4885NR3C1 36/4885 |
| US-20040014798-A1 | Cyclothiocarbamate derivatives as progesterone receptor modulators and methods of treating skin disorders | NR5A1, MC1R, CYP17A1 | PGR 7/4885NR3C1 17/4885 |
| US-20230346820-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | ACE2, SARS1, ACE | PGR 2132/4885NR3C1 921/4885 |
| US-20060009428-A1 | Cyclic progestin regimens and kits | CYP19A1, SHBG, GNRHR | PGR 8/4885NR3C1 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.